(Q38198487)

30 August 2017

The paradigm of mutant p53-expressing cancer stem cells and drug resistance (English)

1 reference

30 August 2017

neoplastic stem cells

1 reference

Yoav Shetzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Hilla Solomon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Alina Molchadsky

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stav Horesh

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

21 March 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

1196-1208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24658181%20AND%20SRC:MED&resulttype=core&format=json

Hallmarks of Cancer: The Next Generation

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The first 30 years of p53: growing ever more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Tumor spectrum analysis in p53-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 family in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

High-frequency developmental abnormalities in p53-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 regulates maternal reproduction through LIF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The p53 family: guardians of maternal reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 in embryonic development: maintaining a fine balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

P53 associates with trk tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. Simultaneous differentiation and proliferation subsequent to p53 functional inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

NGF-mediated transcriptional targets of p53 in PC12 neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 regulates myogenesis by triggering the differentiation activity of pRb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 family members in myogenic differentiation and rhabdomyosarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The transcriptional and signalling networks of pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Strategies for homeostatic stem cell self-renewal in adult tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Stem cells and their niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Regulation of p53 in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53: the barrier to cancer stem cell formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cell fate plug and play: direct reprogramming and induced pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Forcing cells to change lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer genes hypermethylated in human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cellular reprogramming and cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Senescence impairs successful reprogramming to pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Suppression of induced pluripotent stem cell generation by the p53-p21 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Linking the p53 tumour suppressor pathway to somatic cell reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The Ink4/Arf locus is a barrier for iPS cell reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Molecular Biology of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Two faces of p53: aging and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Analysis of ku80-mutant mice and cells with deficient levels of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cellular senescence in cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

P53 and aging: A fresh look at an old paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Modulation of mammalian life span by the short isoform of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

21 January 2018

The hallmarks of aging

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53: one name, many proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

TP53 mutants in the tower of babel of cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Transcriptional control of the proliferation cluster by the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 and genomic instability in a transgenic mouse model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 drives invasion by promoting integrin recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Tumour-associated mutant p53 drives the Warburg effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Caught in the cross fire: p53 in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Modulation of the vitamin D3 response by cancer-associated mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Transactivation of the EGR1 gene contributes to mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mutant p53 gain-of-function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Stem cell concepts renew cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer stem cells--old concepts, new insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Identification and expansion of human colon-cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Complexity of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Ovarian cancer stem cells enrichment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Identification of cells initiating human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer stem cell definitions and terminology: the devil is in the details.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Plasticity of adult stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Stem cells: The promises and perils of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Role of the murine reprogramming factors in the induction of pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mosaic analysis with double markers reveals tumor cell of origin in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Modeling sarcomagenesis using multipotent mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer stem cells in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Normal stem cells and cancer stem cells: the niche matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Cancer drug resistance: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

ABC transporters, drug resistance, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Aldehyde dehydrogenase gene superfamily: the 2002 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The role of human aldehyde dehydrogenase in normal and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Glutathione in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

The ATP-dependent glutathione S-conjugate export pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Glutathione levels and variability in breast tumors and normal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

In vitro studies on the mechanisms of oxaliplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Mechanisms of chemoresistance to alkylating agents in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Senescence evasion by MCF-7 human breast tumor-initiating cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53 Research: the past thirty years and the next thirty years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Translating p53 into the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

p53: traffic cop at the crossroads of DNA repair and recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073

Two Supporting Factors Greatly Improve the Efficiency of Human iPSC Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGU073